Research Article
Syntheses, Characterization, Resolution, and Biological Studies of Coordination Compounds of Aspartic Acid and Glycine
Table 3
Antimicrobial activities of the compounds.
| | | Zone of inhibition (size measured included 6.0 mm of the filter paper disc) | | Microorganism | Na[Cu(L1)3] | Na[Co(L1)3] | Na[Ni(L1)3] | Na[Co(L2)3] | Na[Cd(L1)3] | Na[Mn(L1)3] | [Cu(L2)2] | Acriflavine | | P | R | P | R | P | R | P | R |
| | E. coli | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 8.0 ± 0.9 | 9.0 ± 0.3 | 8.0 ± 0.1 | 6.0 | 6.0 | 6.0 | 20.0 ± 0.4 | | Ps. aeruginosa | 6.0 | 6.0 | 11.0 ± 0.3 | 8.0 ± 0.2 | 6.0 | 6.0 | 20.2 ± 0.1 | 24.0 ± 0.4 | 6.0 | 8.0 ± 0.5 | 6.0 | 6.0 | | P. vulgaris | 6.0 | 6.0 | 14.0 ± 0.5 | 6.0 | 6.0 | 6.0 | 9.0 ± 0.2 | 11.0 ± 0.6 | 6.0 | 14.0 ± 0.8 | 6.0 | 15.0 ± 0.6 | | S. aureus | 6.0 | 16.0 ± 0.3 | 6.0 | 12.0 ± 0.2 | 6.0 | 6.0 | 13.0 ± 0.5 | 6.0 | 6.0 | 8.0 ± 0.1 | 6.0 | 20.0 ± 0.2 | | B. subtilis | 6.0 | 6.0 | 9.0 ± 0.3 | 18.0 ± 0.8 | 6.0 | 6.0 | 13.1 ± 1,0 | 16.0 ± 0.3 | 6.0 | 8.0 ± 0.6 | 6.0 | 6.0 | | MRSA | 6.0 | 6.0 | 6.0 | 8.0 ± 0.4 | 6.0 | 8.0 ± 0.5 | 15.0 ± 0.0 | 16.0 ± 0.2 | 6.0 | 20.0 ± 0.4 | 6.0 | 6.0 | | C. albicans | 6.0 | 6.0 | 18 ± 0.2 | 24.0 ± 0.5 | 18.0 ± 0.5 | 9.0 ± 0.1 | 6.0 | 6.0 | 18.0 ± 0.5 | 6.0 | 6.0 | 19.0 ± 0.1 |
|
|
L1: aspartic acid; L2: glycine; P: parent compounds of Na[Cu(L1)3], Na[Co(L1)3], Na[Ni(L1)3], Na[Co(L2)3], and Na[Cd(L1)3]; R: parent compounds’ respective resolved forms; E. coli: Escherichia coli NCTC 8196; Ps. aeruginosa: Pseudomonas aeruginosa ATCC 19429; P. vulgaris: Proteus vulgaris NCIB; S. aureus: Staphylococcus aureus NCTC 6571; B. subtilis: Bacillus subtilis NCIB 3610; MRSA: methicillin-resistant S. aureus clinical isolate; C. albicans: Candida albicans NCYC 6.
|
